Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
about
Icotinib is an active treatment of non-small-cell lung cancer: a retrospective studyNetwork meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsThird-line systemic treatment for non-small cell lung cancerFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerEthnic background and genetic variation in the evaluation of cancer risk: a systematic reviewTrials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and FutureMolecular biology of lung cancerFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerThe role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerCancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerUnderstanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Afatinib in Non-Small Cell Lung CancerMolecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinomaThe Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-AnalysisOral targeted therapy for cancerRole of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present eraNovel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapiesTreatment of advanced squamous cell carcinoma of the lung: a reviewLung cancer biomarkers, targeted therapies and clinical assaysChina experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Targeting RTK Signaling Pathways in CancerAdvances in Diagnosis and Treatment of Multiple Primary Lung CancerThe influence of subclonal resistance mutations on targeted cancer therapyIdentifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancerCurrent Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted TherapyEvaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerThe Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-AnalysisNovel targeted agents for the treatment of lung cancer in ChinaPrevention and management of lung cancer in ChinaDifferences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese populationThe Evolution of Therapies in Non-Small Cell Lung CancerA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
P2860
Q21132047-A2938F42-9E76-4FF6-BB93-387E0BCF1316Q21132357-FD8C0258-DA8D-44D2-8769-4BB4EFB8EA9DQ24194090-104CD25E-2E90-4B6B-B92D-56EEA5944F04Q24201207-A80BE96D-819C-4497-A4F8-6C578A492F0FQ24288685-C7E3C03F-EA2C-42F2-9ABE-9091C0E03ADBQ24564024-878BE251-565E-47BD-A89D-68E484D1A273Q24606677-171D1061-5084-44CA-9F44-44F8DB9AE1CAQ26471909-7B428389-F699-4FD5-8452-B2EF40186317Q26740529-3A1365B1-07D2-4A59-B719-E78E825A89CCQ26741009-83733EAE-3B82-4904-B5AE-A8316C193D14Q26741814-CFBFF5D2-2B05-4F5A-B1D6-55FBB1D140BBQ26744284-97CA6751-8D9E-43BD-8EF0-3C645678EC60Q26744339-172C1ABA-AFCE-4124-BA54-A8AC1748FEDDQ26745427-0F2659BD-E7B1-4EC0-BA4E-FB9ACFACF447Q26748581-9D33F779-0102-4236-A08B-2FE845ABC2E9Q26749005-89626AF9-20B2-4DB4-A7B7-62985490B702Q26767182-054CF282-4D60-4FDB-B7AB-1BB46D98D964Q26772052-3D4926B0-594F-4FFC-B615-1616C55DB208Q26773240-680DEE19-040B-445A-BDA5-581695A8AED4Q26774726-F1C4D8AC-5962-41DF-8B49-65ECB59F6943Q26775388-C05F04BB-6B99-4725-A703-65B414BBF8A9Q26775392-8B4160BC-30D7-4DEC-96DC-82728CF33C0CQ26775396-29031C12-8556-4763-956F-9783326B9683Q26775603-DFB6FC44-B827-41FD-A6CA-EC8B3D7CAE56Q26775677-D02F64B8-170A-45EF-A856-8FF5527DC3DEQ26778298-FD867016-744D-4463-99B0-2383296446D5Q26778318-AB908D8C-2821-41A0-A78B-CD903FF7826BQ26781278-F2FF5209-9281-4BAA-9637-9E7D821E6382Q26781686-0FAD1A11-5C88-4E12-A410-8FF7AB9247E2Q26781693-EC8868AB-CDF5-4FA9-A540-E1C5F2938330Q26781810-1869AA54-683B-4275-8DDE-EA006143FF64Q26783432-66222B6F-6FBF-40BC-ACEB-BC1F14CF60F6Q26783895-0EC41210-D5C7-4E58-A6B4-7CC2080D4BB4Q26784298-DB4A4EE7-4322-4265-A6FB-C5D6BAE93A9DQ26786142-EC17E01D-5225-42C0-96CD-66B78FE54548Q26786580-136C0806-B604-4C96-8625-1D18665EA3D7Q26786585-9C269C6A-BD6B-4F86-B5A2-FCDBC640DE9BQ26786594-DC2B78F9-E347-4B3E-92F8-15C7C4A9515FQ26786932-28F94016-4ECF-4CB9-ACD4-A7311B9EF2EFQ26797297-D9A824BE-9FD9-4D0A-B22B-02834AFBF1FA
P2860
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Erlotinib versus chemotherapy ...... bel, randomised, phase 3 study
@ast
Erlotinib versus chemotherapy ...... bel, randomised, phase 3 study
@en
type
label
Erlotinib versus chemotherapy ...... bel, randomised, phase 3 study
@ast
Erlotinib versus chemotherapy ...... bel, randomised, phase 3 study
@en
prefLabel
Erlotinib versus chemotherapy ...... bel, randomised, phase 3 study
@ast
Erlotinib versus chemotherapy ...... bel, randomised, phase 3 study
@en
P2093
P3181
P1433
P1476
Erlotinib versus chemotherapy ...... bel, randomised, phase 3 study
@en
P2093
Caicun Zhou
Changli Wang
Changxuan You
Chengping Hu
Chunhong Hu
Gongyan Chen
Jianan Huang
Jifeng Feng
P304
P3181
P356
10.1016/S1470-2045(11)70184-X
P407
P50
P577
2011-07-23T00:00:00Z